A physician and patient with obesity model a discussion on mitigating the patient’s risk for heart failure with strategies for weight loss and increased physical activity.

Identify which patients are most likely to benefit from PCSK9 inhibition for the treatment of hypercholesterolemia.

Describe the pathophysiology of Fabry disease causing renal and cardiac complications

Describe the latest research being presented to better manage MPS II and its clinical relevance.

Review the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in patients with primary and secondary hyperlipidemia.

To provide learners with a comprehensive education on the assessment, diagnosis, and management/support of individuals and families with Pompe Disease, that addresses knowledge and competence gaps to contribute to suboptimal care.  

Contrast the spectrum and symptomatology of Fabry disease (FD) in women vs men and and apply appropriate, gender-specific diagnostic criteria to women suspected of FD

Review current and emerging treatment options for patients with PAH and develop strategies to effectively identify side effects and optimize patient outcomes